The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases

Neurochemical Research

Volumn 33, Issue 2, 2008, Pages 318-327

  Contestabile, Antonio ^a   Ciani, Elisabetta ^a   Contestabile, Andrea ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aging; Alzheimer's disease; Animal models; Dementia; Down's syndrome; Forebrain cholinergic system

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CHOLINE ACETYLTRANSFERASE; GLUTAMATE AMMONIA LIGASE; MUSCARINIC RECEPTOR; NEUROTROPHIN RECEPTOR P75;

ACETYLCHOLINE RELEASE; AGING; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BIOCHEMISTRY; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CHROMOSOME 16; CHROMOSOME 21; COGNITIVE DEFECT; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISEASE MODEL; DOWN SYNDROME; ENZYME ACTIVITY; FOREBRAIN; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; LEARNING DISORDER; NEUROTRANSMISSION; NONHUMAN; OCCIPITAL CORTEX; OLFACTORY BULB; OLFACTORY CORTEX; PARIETAL LOBE; PRIORITY JOURNAL; SENILE PLAQUE;

ANIMALS; CHOLINE O-ACETYLTRANSFERASE; HUMANS; MODELS, ANIMAL; NEURODEGENERATIVE DISEASES; RECEPTORS, CHOLINERGIC;

ANIMALIA;

EID: 38349154106     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9497-4     Document Type: Article

References (103)

1. Fonnum F (1975) A rapid radiochemical method for the determination of choline actyltransferase. J Neurochem 24:407-409
2. Eckstein F, Thoenen H (1982) Production of specific antisera and moniclonal antibodies to choline acetyltransferase: characterization and use for identification of cholinergic neurons. EMBO J 1:363-368
3. Armstrong DM, Saper CB, Levey AI et al (1983) Distribution of cholinergic neurons in rat brain: demonstrated by the immunocytochemical localization of choline acetyltransferase. J Comp Neurol 216:53-68
4. Woolf NJ, Eckenstein F, Butcher LL (1984) Cholinergic systems in rat brain: I. projections to the limbic telencephalon. Brain Res Bull 13:751-784
5. Bartus RT, Dean R, Beer B, Lippa A (1982) The cholinergic hypothesis of geriatric memory disfunction. Science 217:408-417
6. Bartus RT (2000) On neurodegenerative diseases, models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495-529
7. Morris JC (2002) Challenging assumptions about Alzheimer's disease: mild cognitive impairment and the cholinergic hypothesis. Ann Neurol 51:143-144
8. Sarter M, Bruno JP (2002) Mild cognitive impairment and the cholinergic hypothesis: a very different take on recent data. Ann Neurol 52:384-385
9. Terry AV, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306:821-827
10. Buccafusco JJ, Terry AV Jr (2000) Multiple CNS targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 295:438-446
11. Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403
12. Perry EK, Gibson PK, Blessed G et al (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34:247-265
13. Whitehouse P, Price DL, Struble RG et al (1982) Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237-1239
14. Davis KL, Mohs RC, Marin D et al (1999) Cholinergic markers in elderly patients with early signs of Alzheimer's disease. J Am Med Ass 281:1401-1406
15. Tiraboschi P, Hansen LA, Alford M et al (2000) The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology 55:1278-1283
16. DeKosky ST, Ikonomovic MD, Styren SD et al (2002) Upregulation of choline acetyltransferase activity In hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:145-155
17. Gilmor MI, Erickson JD, Varoqui H et al (1999) Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 411:693-704
18. Mufson EJ, Ma SY, Cochran EJ et al (2000) Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 427:19-30
19. Chu Y, Cochran EJ, Bennet DA et al (2001) Downregulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 443:136-153
20. Mufson EJ, Ma SY, Dills J et al (2002) Loss of basal forebrain P75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 443:136-153
21. Mufson EJ, Bothwell M, Hersh LB, Kordower JH (1989) Nerve growth factor receptor immunoreactive profiles in the normal, aged human basal forebrain: colocalization with cholinergic neurons. J Comp Neurol 285:196-217
22. Mufson EJ, Ginsberg S, Ikonomovic MD, DeKosky ST (2003) Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 26:233-242
23. Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition and treatment strategies. Prog Neurobiol 68:209-245
24. Picciotto MR, Zoli M (2002) Nicotinic recptors in aging and dementia. J Neurobiol 53:641-655
25. Sofroniew MV, Howe CL, Mobley WC (2001) Nerve growth factor signaling, neuroprotection and neural repair. Annu Rev Neurosci 24:1217-1281
26. Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T (1999) Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 57:451-484
27. Dai J, Buijs RM, Kamphorst W, Swaab DF (2002) Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Res 948:138-144
28. Counts SE, Mufson EJ (2005) The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer's disease. J Neuropath Exp Neurol 64:263-272
29. Ikonomovic MD, Mufson EJ, Wuu J et al (2003) Cholinergic plasticity in hippocampus with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimer Dis 5:39-48
30. Gomez-Isla T, Price JL, Mckeel DW Jr et al (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16:4491-4500
31. Kordower JH, Chu Y, Stebbins JT et al (2001) Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 49:202-213
32. Allen SJ, MacGowan SH, Tyler S, Wilcock GK et al (1997) Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci Lett 239:33-36
33. Lai MK, Tsang SW, Garcia-Alloza M, Minger SL (2006) Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. Neurobiol Dis 22:551-561
34. Corey-Bloom J, Tiraboschi P, Hansen LA, Alford M et al (2000) E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease. Neurology 54:403-406
35. Tiraboschi P, Hansen LA, Masliah E, Alford M et al (2004) Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer's disease. Neurology 62:1977-1983
36. Pomara N, Willoughby LM, Wesnes K, Sidtis JJ (2004) Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study. Neuropsychopharmacology 28:403-409
37. Wirths O, Multhaup G, Bayer TA (2004) A modified β-amyloid hypothesis: intraneuronal accumulation of the β-amyloid peptide-the first step of a fatal cascade. J Neurochem 91:513-520
38. Cuello CA (2005) Intracellular and extracellular Aβ, a tale of two neuropathologies. Brain Pathol 15:66-71
39. Snyder EM, Nong Y, Almeida CG et al (2005) Regulation of NMDA receptor trafficking by amyloid-β. Nature Neurosci 8:1051-1058
40. Tanzi RE (2005) The synaptic Aβ hypothesis of Alzheimer disease. Nature Neurosci 8:977-979
41. Beach TG, Kuo YM, Spiegel K et al (2000) The cholinergic deficit coincides with Abeta deposition at the earliest histopathological stages of Alzheimer disease. J Neuropathol Exp Neurol 59:308-313
42. Jhamandas JK, Cho C, Jassar B et al (2001) Cellular mechanisms for amyloid-β-protein activation of rat cholinergic basal forebrain neurons. J Neurophysiol 86:1312-1320
43. Liu Q-S, Kawai H, Berg DW (2001) β-amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 98:4734-4739
44. Selkoe DJ (2002) Alzheinmer's disease is a synaptic failure. Science 298:789-791
45. Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68:209-245
46. Page KJ, Everitt BJ, Robbins TW et al (1991) Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: differential dependence on cholinergic neuron loss. Neuroscience 43:457-472
47. Robbins TW, Everitt BJ, Marston HM et al (1989) Comparative effects of ibotenic acid- and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes. Behav Brain Res 35:221-240
48. Waite JJ, Chen AD, Wardlow ML et al (1995) 192 immunoglobulin G-saporin produces graded behavioral and biochemical changes accompanying the loss of cholinergic neurons of the basal forebrain and cerebellar Purkinje cells. Neuroscience 65:463-476
49. Schliebs R, Rossner S, Bigl V (1996) Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. Prog Brain Res 109:253-264
50. Calzà L, Giuliani A, Fernandez M et al (2003) Neural stem cells and cholinergic neuron: regulation by immunolesion and treatment with mitogens, retinoic acid and nerve growth factor. Proc Natl Acad Sci USA 100:7325-7330
51. Ruberti F, Capsoni S, Comparini A et al (2000) Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen and skeletal muscle distrophy. J Neurosci 20:2581-2601
52. Capsoni S, Ugolini G, Comparini A et al (2000) Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA 97:6826-6831
53. Passavento E, Capsoni S, Domenici L, Cattaneo A (2002) Acute cholinergic rescue of synaptic plasticity in the neurodegenerating cortex of anti-nerve-growth-factor mice. Eur J Neurosci 15:1030-1036
54. Van Leuven F (2000) Single and multiple transgenic mice as models for Alzheimer's disease. Prog Neurobiol 61:306-312
55. Wong PC, Cai H, Borchelt DR, Price DL (2002) Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci 5:633-639
56. Borchelt DR, Ratoviski T, van Lare J et al (1997) Accelerated amyloid depositionin the brains of transgenic mice co-expressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939-945
57. Calhoun ME, Burgermeister P, Phinney AL et al (1999) Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA 96:14088-14093
58. Chen G, Chen KS, Knox J et al (2000) A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease. Nature 405:975-979
59. Mucke L, Masliah E, Yu GQ et al (2000) High level neuronal expression of Aβ1-42 in wild type human amyloid precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050-4058
60. Oddo B, Caccamo A, Sheperd JD et al (2003) Triple transgenic model of Alzheimer's disease with plaques And tangles: intracellular Aβ and synaptic dysfunction. Neuron 39:409-421
61. Irizarry MC, Soriano F, McNamara M et al (1997) Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17:7053-7059
62. Calhoun ME, Wiederhold KH, Abramowski D et al (1998) Neuron loss in APP transgenic mice. Nature 395:755-756
63. Chui DH, Tanahashi H, Ozawa K et al (1999) Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 5:560-564
64. Takeuchi A, Irizarry MC, Duff K et al (2000) Age-related amyloid β deposition in transgenic mice overexpressing both Alzheimer mutant presenilin1 and amyloid β precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol 157:331-339
65. Urbanc B, Cruz L, Le R et al. (2002) NEurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc Natl Acad Sci USA 99:13990-13995
66. Schmitz C, Rutten BPF, Pielen A et al (2004) Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 164:1495-1502
67. Casas C, Sergeant N, Itier J-M et al (2004) Massive CA1/2 neuronal loss with intraneuronal and n-terminal truncated A 42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165:1289-1300
68. Wong TP, Debeir T, Duff K, Cuello AC (1999) Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci 19:2706-2716
69. Jaffar S, Counts SE, Ma SY et al (2001) Neuropathology of mice carrying mutant APPSWE and/or PS1M146L transgenes: alterations in p75NTR cholinergic basal forebrain septohippocampal pathway. Exp Neurol 170:227-243
70. Hernandez D, Sugaya K, Qu T et al (2001) Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid protein mutant genes. Neuroreport 12:1377-1384
71. German DC, Yazdani U, Speciale SG et al (2003) Cholinergic neuropathology in a mouse model of Alzheimer's disease. J Comp Neurol 462:371-381
72. Gau JT, Steinhilb ML, D'Amato CJ et al (2002) Stable beta secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am J Pathol 160:731-738
73. Apelt J, Kumar A, Schliebs R (2002) Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swidish mutation of human beya-amyloid precursor protein. Brain Res 953:17-30
74. Luth HJ, Ihunvo AO, Arendt T, schliebs R (2003) Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice. Brain Res 977:16-22
75. Buttini M, Yu GQ, Shockley K et al (2002) Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci 22:10539-10548
76. Feng Z, Chang Y, Cheng Y et al (2004) Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 37:129-136
77. Hartmann J, Erb C, Ebert U et al (2004) Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice. Neuroscience 125:1009-1017
78. Van Dam D, Marescau B, Engelborghs et al (2005) Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochem Int 46:409-422
79. Hayes A, Batshaw ML (1993) Down syndrome. Pediatr Clin North Am 40:523-529
80. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia in Alzheimer's disease and Down's syndrome. Ann Neurol 17:278-282
81. Mann DM, Esiri MM (1989) The pattern of acquisition of plaques and tangles in the brain of patients under 50 years of age with Down's syndrome. J Neurol Sci 89:169-179
82. Casanova MF, Walker LC, Whitehous PJ, Price DL (1985) Abnormalities of the nucleus basalis In Down's syndrome. Ann Neurol 18:310-313
83. Goodrige H, Reynolds GP, Czudek C et al (1987) Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J Neurol Neurosur Psychyat 50:775-778
84. Fodale V, Mafrica F, Caminiti V, Grasso G (2006) The cholinergic system in Down's syndrome. J Intellect Disabil 10:261-274
85. Kish S, Karlinsky H, Becker L et al (1989) Down's syndrome individuals begin life with normal levels of brain cholinergic markers. J Neurochem 52:1183-1187
86. Korenberg JR, Chen XN, Schipper R et al (1994) Down syndrome phenotypes: the consequence of chromosomal imbalance. Proc Natl Acad Sci USA 91:4997-4501
87. Coyle JT, Oster-Granite ML, Reeves MH, Gearhart JD (1988) Down syndrome, Alzheimer's disease and the trisomy 16 mouse. Trends Neurosci 11:390-394
88. Holtzman DM, Kilbridge J, Chen KS et al (1995) Preliminary characterization of the central nervous system in partial trisomy 16 mice. Prog Clin Biol Res 393:227-240
89. Flieder JL, Epstein CJ, Rapoport SI et al (1994) Regional alterations of cholinergic function in central neurons of trisomy 16 mouse fetuses, an animal model of human trisomy 21 (Down syndrome). Brain Res 658:27-32
90. Nelson PG, Fitzgerald S, Rapoport SI et al (1997) Cerebral cortical astroglia from the trisomy 16 mouse, a model for Down syndrome, produce neuronal cholinergic deficit in cell culture. Proc Natl Acad Sci USA 94:12644-12648
91. Allen DD, Martin J, Arriagada C et al (2000) Impaired cholinergic function in cell lines derived for the cerebral cortex of normal and trisomy 16 mice. Eur J Neurosci 12:3259-3264
92. Cardenas AM, Arriagada C, Allen DD et al (2002) Cell lines derived from hippocampal neurons of the normal and trisomy 16 mouse fetus (a model for Down syndrome) exhibit neuronal markers, cholinergic function and functional neurotransmitter receptors. Exp Neurol 177:159-170
93. Davisson MT, Schmidt C, Akeson EC (1990) Segmental trisomy of murine chromosome 16: a new model for studying Down syndrome. Prog Clin Biol Res 360:263-280
94. Escorihuela RM, Fernandez-Teruel A, Vallina IF et al (1995) A behavioral assessement of Ts65Dn mice: aputative Down's syndrome model. Neurosci Lett 247:171-174
95. Reeves RH, Irving NJ, Moran TH et al (1995) A mouse model of Down syndrome exhibits learning and behavior deficits. Nature Gen 11:177-184
96. Holtzman DM, Santucci D, Kilbridge J et al (1996) Developmental abnormalities and age-related neurodegenerationin a mouse model of Down syndrome. Proc Natl Acad Sci USA 93:13333-13338
97. Granholm AC, Sanders LA, Crnic LS (2000) Loss of cholinergic phenotype in basal forebrain coincides with cognitive declinein a mouse model of Down's syndrome. Exp Neurol 161:647-663
98. Hunter CL, Bimonte HA, Granholm AC (2003) Behavioral comparison of 4 and 6 month-old Ts65Dn mice: age-related impairments in working and reference memory. Behav Brain Res 138:121-131
99. Seo H, Isacson O (2005) Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp Neurol 193:469-480
100. Cooper JD, Salehi A, Delcroix J-D et al (2001) Failed retrograde transport of NGF In a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 98:10439-10444
101. Contestabile A, Fila T, Bartesaghi R et al (2006) Choline acetyltransferase activity at different ages in brain Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. J Neurochem 97:515-526
102. Sunderland T, Esposito G, Molchan SE et al (1995) Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study. Psychopharmacology 121:231-241
103. Kleschevnikov AM, Belichenko PV, Villar AJ et al (2004) Hippocampal long term potentiation suppressed by increased inhibition in the Ts65Dn mouse model of Down's syndrome. J Neurosci 24:8153-8160